CP

Caligan Partners Portfolio holdings

AUM $515M
This Quarter Return
+17.43%
1 Year Return
+70.09%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$315M
AUM Growth
+$315M
Cap. Flow
-$137M
Cap. Flow %
-43.47%
Top 10 Hldgs %
98.4%
Holding
13
New
–
Increased
5
Reduced
6
Closed
1

Top Buys

1
YMAB icon
Y-mAbs Therapeutics
YMAB
$8.06M
2
AGIO icon
Agios Pharmaceuticals
AGIO
$2.89M
3
MLYS icon
Mineralys Therapeutics
MLYS
$2.85M
4
EOLS icon
Evolus
EOLS
$416K
5
IMAB
I-MAB
IMAB
$154K

Top Sells

1
ALIM
Alimera Sciences, Inc.
ALIM
$93.6M
2
LQDA icon
Liquidia Corp
LQDA
$22.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
$15.3M
4
VRNA
Verona Pharma
VRNA
$11.7M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
$7.46M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$2.38B
$81.2M 25.73%
8,118,592
-2,242,353
-22% -$22.4M
VRNA
2
Verona Pharma
VRNA
$9.16B
$41.3M 13.1%
1,436,878
-406,878
-22% -$11.7M
EXEL icon
3
Exelixis
EXEL
$10.1B
$39.6M 12.55%
1,525,730
– –
EOLS icon
4
Evolus
EOLS
$494M
$35.5M 11.26%
2,193,488
+25,698
+1% +$416K
ANIK icon
5
Anika Therapeutics
ANIK
$135M
$35.4M 11.24%
1,435,130
-863
-0.1% -$21.3K
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.19B
$25.8M 8.16%
579,717
+65,006
+13% +$2.89M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$1.74B
$19.6M 6.22%
2,583,585
-2,015,152
-44% -$15.3M
YMAB icon
8
Y-mAbs Therapeutics
YMAB
$388M
$15.7M 4.98%
1,195,253
+613,175
+105% +$8.06M
MLYS icon
9
Mineralys Therapeutics
MLYS
$1.03B
$11.9M 3.77%
981,155
+235,397
+32% +$2.85M
IMAB
10
I-MAB
IMAB
$340M
$4.34M 1.38%
3,499,330
+124,539
+4% +$154K
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$180M
$3.34M 1.06%
322,453
-720,436
-69% -$7.46M
OTLK icon
12
Outlook Therapeutics
OTLK
$37.8M
$1.7M 0.54%
318,699
-181,301
-36% -$968K
ALIM
13
DELISTED
Alimera Sciences, Inc.
ALIM
– –
-16,835,154
Closed -$93.6M